We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

34 hedge funds and large institutions have $7.6M invested in Protalix BioTherapeutics in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 5

21% more funds holding

Funds holding: 28 → 34 (+6)

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

16% more call options, than puts

Call options by funds: $202K | Put options by funds: $174K

0.03% more ownership

Funds ownership: 0.68% → 0.72% (+0.03%)

34% less capital invested

Capital invested by funds: $11.5M → $7.6M (-$3.89M)

Holders
34
Holders Change
+6
Holders Change %
+21.43%
% of All Funds
0.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
7
Reduced
6
Closed
5
Calls
$202K
Puts
$174K
Net Calls
+$28K
Net Calls Change
+$115K

Top Buyers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
+$663K
2
OAM
Oxford Asset Management
United Kingdom
+$646K
3
Renaissance Technologies
Renaissance Technologies
New York
+$350K
4
UBS Group
UBS Group
Switzerland
+$347K
5
UOC
UBS O'Connor
Illinois
+$305K

Top Sellers

Rank Fund Capital Flow
1
IAM
Ion Asset Management
Israel
-$2.14M
2
Federated Hermes
Federated Hermes
Pennsylvania
-$186K
3
Jane Street
Jane Street
New York
-$111K
4
Simplex Trading
Simplex Trading
Illinois
-$104K
5
WAM
Wolverine Asset Management
Illinois
-$98.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$16K +$5.32K +567 +44%
Simplex Trading
27
Simplex Trading
Illinois
$15K -$104K -11,044 -86%
Citigroup
28
Citigroup
New York
$11K +$12.3K +1,310 New
CB
29
Commerce Bank
Missouri
$8K +$9.39K +1,000 New
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
$4K – – –
SEI Investments
31
SEI Investments
Pennsylvania
$3K +$3.01K +321 New
FDCDDQ
32
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.1K – – –
PCM
33
Prelude Capital Management
New York
$2K +$1.88K +200 New
ASN
34
Advisory Services Network
Georgia
$1K +$939 +100 New
IAM
35
Ion Asset Management
Israel
– -$2.14M -157,171 Closed
WAM
36
Wolverine Asset Management
Illinois
– -$98.5K -10,494 Closed
Citadel Advisors
37
Citadel Advisors
Florida
– -$96.2K -10,250 Closed
Commonwealth Equity Services
38
Commonwealth Equity Services
Massachusetts
– -$51K -3,775 Closed
Manulife (Manufacturers Life Insurance)
39
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$1K -54 Closed
1
2

PLX Hedge Fund Activity: Q2 2017 in Review

34 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2017, worth a combined $7.6M — down 34% from $11.5M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new PLX positions and 5 closed out — a net gain of 6 holders — while 7 added to existing stakes and 6 trimmed.

The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $663K. The largest seller was Ion Asset Management, exiting entirely with an estimated $2.14M sold.

  • 34 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2017, up from 28 in Q1 2017.
  • Funds reported $7.6M of Protalix BioTherapeutics stock for Q2 2017, down 34% quarter-over-quarter.
  • 11 funds opened new Protalix BioTherapeutics positions in Q2 2017 and 5 closed out, a net change of +6 holders.
  • The largest Protalix BioTherapeutics buyer in Q2 2017 was Virtu KCG Holdings, an estimated $663K added.
  • The largest Protalix BioTherapeutics seller in Q2 2017 was Ion Asset Management, an estimated $2.14M sold.

Based on aggregated 13F filings for Q2 2017.